Buzz: GSK plots board coup in HGS flank attack

Forget the usual thin-end-of-the-wedge proxy-fight strategy. Rather than nominating a few directors to push its buyout agenda at Human Genome Sciences ($HGSI), GlaxoSmithKline ($GSK) plans a campaign…
Read the full story: News